• Bobby Indra Utama Sub Division of Urogynecology, Obstetrics and Gynecology Department, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang



Amniotic fluid is a liquid that fills the amniotic cavity which has defense and nutritional functions in fetal development. Human aterm amniotic fluid can be an ideal alternative as a source of mesenchymal stem cells, originating from the neonate. Preclinical studies of second and third trimester amnion fluid cells confirmed the number of potential donors from this wasted material. In several studies, AF-MSCs express mesenchymal markers such as CD90, CD73 (SH3, SH), CD105 (SH2), CD29, CD166, CD49e, CD58 and CD44 (MHC class I). These cells also express HLA-ABC antigens, CD 34, CD 45 which are hematopoietic markers, and endothelial CD31 markers. There is no expression of CD10, CD11b, CD14, CD34, CD117, EMA and HLA-DR, DP, DQ antigens. Most of AF-MSCs have pluripotent properties which are characterized by the discovery of octamer binding protein 3/4 (Oct-3/4), transcription factors Nanog (Nanog), and stage-specific embryonic antigen 4 (SSEA-4) on RT-PCR examination. From this study, 8 million cells was isolated. These cells will be used for research on pelvic organ prolapse therapy by using AF-MSCs. AF-MSCs isolation totally takes 6 weeks. From 1 flask, 2 million of stem cells was obtained.

Keywords: amniotic fluid, AF-MSCs


DeSacco S D, DeFilippo R E, Perin L, 2011. Amniotic fluid as a source of pluripotent and multipotent stem cells for organ regeneration. Current Opinion in Organ Transplantation; 16:101–105

Roubelakis MG, Trohatou O, Anagnou NP, 2012. Amniotic Fluid and Amniotic Membrane Stem Cells: Marker Discovery. Stem Cells International; Vol 2012: 1-9

Asl KD, Shafei H, Rad JS, Nozad HO, 2016. Comparison of Characteristics of Human Amniotic Membrane and Human Adipose Tissue Derived Mesenchymal Stem Cells. World Journal of Plastic Surgery; 6(1):33-39.

Gaafar T M, Hawary R E, Osman, A, Attia W, Hamza H, Brockmeier K, 2014. Comparative characteristics of amniotic membrane, endometrium and ovarian derived mesenchymal stem cells: A role for amniotic membrane in stem cell therapy. Middle East Fertility Society Journal; 19:156–170

Moraghebi R, Kirkeby A, Chaves P, et al., 2017. Term amniotic fluid: an unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications. Stem Cell Research & Therapy. Vol 8(190) pg 1-12

Kim BS, Chun SY, Lee JK, Lim HJ et al., 2012. Human amniotic fluid stem cell injection therapy for urethral sphincter regeneration in animal model. BMC Medicine. 1094_ 1-14

Decoppi P, Bartsch G Jr, Siddiqui MM et al, 2007. Isolation of amniotic stem cell lines with potential for therapy. Nature Biotechnology; 25(1): 100-106

Savickiene J., Treigyte G., Baronaite S. et al, 2015. Human Amniotic Fluid Mesenchymal Stem Cells from Second- and Third-Trimester Amniocentesis: Differentiation Potential, Molecular Signature, and Proteome Analysis. Stem Cells International; vol. 2015; 319238 pg 1-15

Tsai MS, Lee JL, Chang YJ, Hwang SM, 2004. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum. Reprod.; 19: 1450–1456

Larson A, Gallichio VS, 2017. Amniotic derived stem cells: role and function in regenerative medicine. Journal of cell science & therapy. 8:3

Steigman SA, Fauza DO, 2007. Isolation of mesenchymal stem cells for amniotic fluid and placenta. Current Protocol Stem Cell Biology. Chap 1: Unit 1 E.2: 533-544

Chamberlain G, Fox J, Ashton B, Middleton J, 2007. Concise Review: Mesenchymal stem cells: Their phenotype, Differentiation capacity, Immunological features, and potential for homing. Stem Cells. 25: 2739-2749

Lim R, 2017. Concise Review: Fetal Membranes in Regenerative Medicine: New Tricks from an Old Dog? Stem Cells Translational Medicine; 6:1767–1776

Dominici M, Blanc KL, Mueller I, et al., 2006. Position Paper: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy; Cytotherapy; Vol 8(4): 315-317